Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
$8.00
+9.3%
$7.76
$3.08
$597.60
$11.60M0.08555,123 shs90,643 shs
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
$1.21
+4.3%
$1.46
$0.95
$5.95
$15.01M1.45176,856 shs58,468 shs
Neuphoria Therapeutics Inc. stock logo
NEUP
Neuphoria Therapeutics
$6.92
-0.3%
$7.44
$2.12
$12.55
$13.05M0.5333,608 shs22,204 shs
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
$4.86
-0.2%
$4.43
$3.03
$9.00
$4.45M1.2951,396 shs89,354 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
-2.27%-17.75%-37.22%-66.58%-97.54%
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
+2.65%-10.08%-24.18%+2.65%-68.82%
Neuphoria Therapeutics Inc. stock logo
NEUP
Neuphoria Therapeutics
-9.16%-12.70%-9.87%+11.40%+693,999,900.00%
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
-3.82%-2.49%+8.16%+6.86%-50.95%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
1.0545 of 5 stars
0.04.00.00.02.12.50.0
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
3.6581 of 5 stars
3.82.00.03.92.60.00.0
Neuphoria Therapeutics Inc. stock logo
NEUP
Neuphoria Therapeutics
1.3519 of 5 stars
3.50.00.00.00.60.00.6
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
0.3195 of 5 stars
0.03.00.00.02.50.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
2.00
HoldN/AN/A
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
3.50
Strong Buy$13.17988.15% Upside
Neuphoria Therapeutics Inc. stock logo
NEUP
Neuphoria Therapeutics
3.00
Buy$21.00203.47% Upside
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
$40K316.00N/AN/A$2.29 per share3.49
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
$6.59M2.38N/AN/A$0.81 per share1.49
Neuphoria Therapeutics Inc. stock logo
NEUP
Neuphoria Therapeutics
$10K1,300.96N/AN/A$15.85 per share0.44
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
$180K24.57N/AN/A$3.05 per share1.59
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
-$11.21M-$839.58N/AN/AN/A-723.64%-145.51%N/A
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
-$10.73M-$1.37N/AN/AN/A-271.12%-114.59%-90.31%N/A
Neuphoria Therapeutics Inc. stock logo
NEUP
Neuphoria Therapeutics
-$15.49MN/A0.00N/AN/AN/AN/AN/A9/29/2025 (Estimated)
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
-$4.71M-$2.95N/AN/AN/A-108.60%-95.64%8/21/2025 (Estimated)

Latest TTNP, NEUP, CYCC, and MRKR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
-$0.55-$0.29+$0.26-$0.29$0.72 million$0.86 million
8/14/2025Q2 2025
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
N/A-$0.65N/A-$0.65N/AN/A
8/13/2025Q2 2025
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
-$72.00-$0.98+$71.02-$0.98$0.03 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
N/AN/AN/AN/AN/A
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
N/AN/AN/AN/AN/A
Neuphoria Therapeutics Inc. stock logo
NEUP
Neuphoria Therapeutics
N/AN/AN/AN/AN/A
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
N/A
5.77
5.60
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
N/A
3.45
6.79
Neuphoria Therapeutics Inc. stock logo
NEUP
Neuphoria Therapeutics
N/A
11.01
11.01
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
N/A
11.60
7.73

Institutional Ownership

CompanyInstitutional Ownership
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
23.58%
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
22.39%
Neuphoria Therapeutics Inc. stock logo
NEUP
Neuphoria Therapeutics
15.90%
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
31.49%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
141.58 million773,000Optionable
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
6012.94 million11.93 millionNot Optionable
Neuphoria Therapeutics Inc. stock logo
NEUP
Neuphoria Therapeutics
N/A1.88 million1.87 millionN/A
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
10910,000907,000Optionable

Recent News About These Companies

Titan Pharmaceuticals Inc (TTNP) - Investing.com
Titan Pharmaceuticals: Q4 Earnings Snapshot
Titan Pharmaceuticals receives Nasdaq notice of non-compliance
Titan Pharmaceuticals, Inc. (TTNP)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cyclacel Pharmaceuticals stock logo

Cyclacel Pharmaceuticals NASDAQ:CYCC

$8.00 +0.68 (+9.29%)
Closing price 04:00 PM Eastern
Extended Trading
$8.04 +0.04 (+0.56%)
As of 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

Marker Therapeutics stock logo

Marker Therapeutics NASDAQ:MRKR

$1.21 +0.05 (+4.31%)
Closing price 04:00 PM Eastern
Extended Trading
$1.20 0.00 (-0.41%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

Neuphoria Therapeutics stock logo

Neuphoria Therapeutics NASDAQ:NEUP

$6.92 -0.02 (-0.29%)
As of 04:00 PM Eastern

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

Titan Pharmaceuticals stock logo

Titan Pharmaceuticals NASDAQ:TTNP

$4.80 -0.07 (-1.33%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California.